← SynDRA
TALETRECTINIB
SynDRA canonical compound SYN0040204 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | ROS1 |
|---|
| Mechanism of action | proto-oncogene tyrosine protein kinase inhibitor |
|---|
| Indication | non-small cell lung cancer (nsclc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- ROS1 INHIBITOR
- Proto-oncogene tyrosine-protein kinase ROS inhibitor
- NTRK1 INHIBITOR
- Neurotrophic tyrosine kinase receptor inhibitor
- NTRK2 INHIBITOR
- NTRK3 INHIBITOR
- proto-oncogene tyrosine protein kinase inhibitor
Drug classes
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
Cross-references
Synonyms
- AB-106
- DS-6051
- DS-6051a
- DS6051b
- GTPL11198
- AB106
- AB 106
- W4141180YD
- RefChem:187307
- TALETRECTINIB FREE BASE
- Taletrectinib (free base)
- Taletrectinib [INN]
- Taletrectinib [USAN]
- Taletrectinib (USAN/INN)
- Taletrectinib [USAN:INN]
- TALETRECTINIB [WHO-DD]
- orb1691639
- SCHEMBL16467983
- SCHEMBL29756133
- UNII-W4141180YD
- EX-A4919
- NSC836439
- WHO 11404
- AKOS040756869
- HY-131003A
- NSC-836439
- DA-78174
- TS-08915
- CS-0131190
- D12363
- F78017
- T38995
- AB-106 ADIPATE
- 6KLL51GNBG
- Taletrectinib adipate [USAN]
- DS-6051b
- MS-30085
- DS-6051b?
- orb1306005
Look up TALETRECTINIB in the interactive SynDRA portal →